Physician profile
Jay S Morrow
NPI 1457424525
$1,026.78
in general payments reported to CMS, 2019-2025
16 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.15 · 2020: $39.60 · 2021: $155 · 2022: $79.74 · 2023: $333 · 2024: $120 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $201.22 | 2020-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $131.89 | 2023 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $101.94 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $90.20 | 2021 | |
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Lilly USA, LLC | $78.70 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $53.22 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $47.48 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $41.71 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $40.68 | 2024-2025 | Xyosted |
| Mannkind Corporation | $34.75 | 2025 | |
| Madrigal Pharmaceuticals | $32.95 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $26.26 | 2025 | Twiist |
| Medtronic, INC. | $21.60 | 2023 | Minimed 780g |
| Recordati_rare_diseases_inc. | $20.40 | 2025 | Isturisa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $16.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.